DAK HEALTH

Non-Exclusive Discount Agreement for Adapalene and Benzoyl Peroxide

This contract involves a non-exclusive discount agreement for the pharmaceutical substances Adapalene and Benzoyl Peroxide, classified under ATC code D10AD23. The agreement is established under Section 130a, Paragraph 8 of the German Social Code (SGB V), allowing health insurance funds and pharmaceu

Published 14 Dec 2025

Non-Exclusive Discount Agreement for Abiraterone

The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the drug Abiraterone (500 mg, 90 tablets) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from December 1, 2025, to November 30, 2027. The process will involve formal procuremen

Non-Exclusive Discount Agreement for Tocilizumab

The German health insurance fund DAK-Gesundheit is seeking suppliers for a non-exclusive discount agreement for the drug Tocilizumab (specifically pre-filled syringes and pens) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from December 1, 2025, to November 30, 2027.

Non-Exclusive Discount Agreement for Pharmaceuticals in Germany

The German Social Code allows health insurance companies and pharmaceutical companies to enter into framework discount agreements for medications covered by statutory health insurance. In accordance with the relevant legal provisions for public procurement, the DAK-Gesundheit will conduct a regular

Non-Exclusive Discount Agreement for Doravirin

The German health insurance companies and pharmaceutical companies can enter into framework discount agreements for medications covered by statutory health insurance, as permitted by § 130a paragraph 8 of the Social Code Book V. The DAK-Gesundheit will conduct a formal procurement process for the ac

Non-Exclusive Discount Agreement for Clobetasol Foam

The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the medication Clobetasol, specifically in foam form (ATC D07AD01). This agreement is part of a framework established under § 130a Abs. 8 SGB V, which allows health insurance companies and pharmaceutical fir

Published 15 Sept 2025

Non-Exclusive Discount Agreement for Calcium Carbonate and Colecalciferol

Published 19 Aug 2025

Non-Exclusive Discount Agreement for Tafluprost + Timolol

The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the medication containing the active ingredients Tafluprost and Timolol (ATC S01ED70). This agreement is in accordance with § 130a Abs. 8 SGB V, which allows health insurance companies and pharmaceutical com

Published 16 Jul 2025

Non-Exclusive Discount Agreement for Umeclidinium

The DAK-Gesundheit is seeking pharmaceutical companies to enter into a non-exclusive discount agreement for the drug Umeclidinium (ATC R03BB07) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from September 1, 2025, to August 31, 2027. The process will follow the formal

Published 16 Jul 2025

Non-Exclusive Discount Agreement for Abrocitinib

The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the drug Abrocitinib (ATC D11AH08) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from September 1, 2025, to August 31, 2027. The process will involve formal procurement proced